Results 151 to 160 of about 24,598 (183)

Carbapenemases: a problem in waiting?

Current Opinion in Microbiology, 2000
Carbapenems are stable to most prevalent beta-lactamases, and chromosomal carbapenemases are restricted to Stenotrophomonas maltophilia, to a few Bacteroides fragilis, and to rare pathogens. Nevertheless, an acquired metallo-beta-lactamase called IMP-1 is beginning to emerge in Pseudomonas aeruginosa and Enterobacteriaceae isolates in Japan, and has ...
D M, Livermore, N, Woodford
openaire   +2 more sources

Emerging carbapenemases: a global perspective

International Journal of Antimicrobial Agents, 2010
The celestial rise in antibiotic resistance among Gram-negative bacteria has challenged both the scientific and pharmaceutical sectors. The hallmark of this general increase is the unbridled dissemination of carbapenem resistance genes, namely KPC, OXA and metallo-β-lactamase variants.
openaire   +2 more sources

[Carbapenemases in enterobacteriaceae].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2011
Carbapenem-hydrolyzing beta-lactamases are the most powerful mechanism of resistance to carbapenems. Carbapenemases have been reported extensively worldwide now in Enterobacteriaceae. Carbapenemases of the KPC type have been reported first from the USA in Klebsiella pneumoniae, then worldwide with a marked endemicity in Israel and Greece.
P, Nordmann, A, Carrer
openaire   +1 more source

[Carbapenemases in Pseudomonas spp].

Enfermedades infecciosas y microbiologia clinica, 2010
Pseudomonas aeruginosa is one of the most relevant nosocomial pathogens, as well as one of the main causes of chronic respiratory infections in patients with underlying diseases such as cystic fibrosis or chronic obstructive pulmonary disease. The high intrinsic antibiotic resistance of this pathogen, together with its extraordinary capacity for ...
Carlos, Juan Nicolau, Antonio, Oliver
openaire   +1 more source

[ESBL and carbapenemases in Enterobacteriaceae].

Revue medicale suisse, 2015
Carbapenemase-producing enterobacteria (CPE) spread all over the world during the last years, causing serious infections with increasing frequency. Very few new drugs active against CPE are expected to be clinically available. Studies summarized in this review show that there is yet room to improve our therapeutic approaches, in the treatment of ...
A, Cherkaoui, S, Emonet, G, Renzi, A, Riat, G, Greub, J, Schrenzel   +5 more
openaire   +1 more source

Genomic Epidemiology of Carbapenemase-Producing Klebsiella Pneumoniae in China

Genomics, Proteomics and Bioinformatics, 2022
Fei Chen, Guannan Ma, Liya Yue
exaly  

Carbapenemase producing Klebsiella pneumoniae: implication on future therapeutic strategies

Expert Review of Anti-Infective Therapy, 2022
Irène Galani, Ilias Karaiskos, Helen Giamarellou   +2 more
exaly  

Carbapenemase-producing Pseudomonas aeruginosa –an emerging challenge

Emerging Microbes and Infections, 2022
Fred C Tenover, David Nicolau
exaly  

Genomic and Phenotypic Diversity of Carbapenemase-Producing Enterobacteriaceae Isolates from Bacteremia in China: A Multicenter Epidemiological, Microbiological, and Genetic Study

Engineering, 2022
Shuntian Zhang, Huiming Han
exaly  

Carbapenemase-Producing Organisms: A Global Scourge

Clinical Infectious Diseases, 2018
Laurent Poirel, Julia Segre, Robert Bonomo   +2 more
exaly